In the next few days , the U.S. Food and Drug Administration is expected to Joint Meeting of the Joint Meeting of the Endocrinologic and Metabolic Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee. This committee was convened to evaluate the scientific research on the safety of rosiglitazone , and then should be a decision on how the drug be used or not. The joint statement recommends that until further clarification is provided by the FDA, is deciding whether or not to use any drugs that the…
Read More